Oppenheimer analyst Jay Olson downgraded Terns Pharmaceuticals (NASDAQ: TERN) from Outperform to Perform.The analyst comments: "MRK's acquisition of TERN for ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE